Medicus Pharma Ltd. Amended Initial Statement of Beneficial Ownership
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3/A
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Smith Andrew Alasdair
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Common Shares, no par value ("Common Shares") | -- | -- | -- |
Holdings:
Stock Option (right to buy) — 100,000 options (Direct);
Common Shares, no par value ("Common Shares") — 164 shares (Direct)
Footnotes (2)
- F1. This amendment is being filed to include Common Shares that were inadvertently omitted from the Form 3 filed by the Reporting Person on July 3, 2025.
- F2. The board of directors of Medicus Pharma Ltd. (the "Board") approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest annually in five equal installments beginning on June 30, 2026. All these options are now vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.